Laboratorios Farmaceuticos Rovi, S.A. (VIE:ROVI)

Market Cap	3.58B
Revenue (ttm)	724.20M
Net Income (ttm)	121.15M
Shares Out	n/a
EPS (ttm)	2.37
PE Ratio	29.51
Forward PE	24.12
Dividend	0.76 (1.17%)
Ex-Dividend Date	Jul 14, 2025

Volume	n/a
Average Volume	n/a
Open	69.40
Previous Close	69.05
Day's Range	69.40 - 70.20
52-Week Range	45.82 - 70.20
Beta	n/a
RSI	79.96
Earnings Date	Feb 23, 2026

About VIE:ROVI

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Pharmaceutical Preparations
• Founded: 1946
• Employees: 2,197
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: ROVI

Financial Performance

In 2024, VIE:ROVI's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.